Du Cheng
Impact in
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 1%
- Nanoplatforms for cancer theranostics
- Graphene and Nanomaterials Applications
- Ultrasound and Hyperthermia Applications
Papers in
- Biomaterials 40
- Nanoparticle-Based Drug Delivery 38
-
- Nanoplatforms for cancer theranostics 26
- Graphene and Nanomaterials Applications 9
- Journals
- Biomaterials (8 papers)Small (5 papers)Journal of Biomedical Nanotechnology (4 papers)Polymer Chemistry (4 papers)RSC Advances (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Du Cheng
95 papers receiving 4.8k citations
Peers
Comparison fields: 5 of 120
- Biomaterials 1.8k
- Biomedical Engineering 2.0k
- Molecular Biology 2.5k
- Polymers and Plastics 313
- Molecular Medicine 106
Countries citing papers authored by Du Cheng
This map shows the geographic impact of Du Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Du Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Du Cheng more than expected).
Fields of papers citing papers by Du Cheng
This network shows the impact of papers produced by Du Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Du Cheng. The network helps show where Du Cheng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Du Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2025 | 3 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 13 | |
| 5 | 2024 | 12 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 2 | |
| 8 | 2022 | 10 | |
| 9 | 2022 | 1 | |
| 10 | 2021 | 139 | |
| 11 | 2021 | 26 | |
| 12 | 2020 | 10 | |
| 13 | 2014 | 15 | |
| 14 | 2014 | 42 | |
| 15 | 2013 | 78 | |
| 16 | 2013 | 140 | |
| 17 | 2012 | 40 | |
| 18 | 2011 | 221 | |
| 19 | 2011 | 165 | |
| 20 | 2011 | 347 |
About Du Cheng
Du Cheng is a scholar working on Biomaterials, Biomedical Engineering, Molecular Biology, Business and International Management and Polymers and Plastics, having authored 96 papers that have together received 4.8k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (47 papers), Nanoparticle-Based Drug Delivery (38 papers), Advanced biosensing and bioanalysis techniques (33 papers), Nanoplatforms for cancer theranostics (26 papers), Graphene and Nanomaterials Applications (9 papers), CRISPR and Genetic Engineering (8 papers), Virus-based gene therapy research (7 papers) and Advanced Nanomaterials in Catalysis (7 papers). The work is most often cited by research in Biomaterials (1.8k citations), Biomedical Engineering (2.0k citations), Molecular Biology (2.5k citations), Polymers and Plastics (313 citations) and Molecular Medicine (106 citations). Du Cheng has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Xintao Shuai, Seyin Zou, Mingqiang Li, Jian Dai, Hong Xiao, Jifeng Chen, Jingguo Li, Shudong Lin, Yong Wang and Tinghui Yin. Their work appears in journals such as Biomaterials, Small, Journal of Biomedical Nanotechnology, Polymer Chemistry and RSC Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.